CrystecPharma receive patent approval in the European Union and China

CrystecPharma are pleased to announce the approval of patent applications for their lead asset, CR002. Applications with China’s National Intellectual Property Administration (CNIPA) and the European Patent Office (EPO) have recently been approved. National filings are ongoing in other key territories.

Crystec are delighted to be granted patents in the EU and China, in the acknowledgment of the innovation of CR002 - a novel, fast acting, inhaled therapy for urge urinary incontinence. This will be the first on-demand product for urge incontinence in the world, and the first treatment to empower patients to actively manage their condition. This new treatment modality is uniquely enabled through the application of Crystec’s proprietary mSAS® (modified Supercritical Anti-Solvent) technology.

The mSAS® platform enables precise control over crystallisation and particle formation, including solid-state, particle size, shape, and composition. The single step process offers a novel approach to addressing age-old problems encountered in the pharmaceutical industry, including poor solubility, stability and bioavailability, ultimately providing distinctive opportunities to accelerate development timelines and simplify formulations whilst optimising performance and efficacy.

CR002 has demonstrated in-vitro and in-vivo proof of concept and has been scaled to commercial cGMP manufacture. The product also has strong clinical Key Opinion Leader and patient support, and the clinical development programme has been outlined with the support of existing partners.

The company is actively seeking co-development and licensing partners for this product. As such, if you would like to learn more about CR002, or Crystec’s mSAS® platform, please get in touch emily.bevis@crystecpharma.com, +44 (0) 7496 328367.

To keep up to date with the latest news from Crystec, please follow us on LinkedIn.